Publications

A phase 1/1B trial of ADI‐PEG 20 plus nab‐paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma

MA Lowery, KH Yu, DP Kelsen, JJ Harding, JS Bomalaski, DC Glassman, ...

A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies.

JJ Harding, MA Lowery, K Uhlitskykh, PJ Wan, CR Hamilton, A Barba, ...

A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC).

MA Lowery, EM O'Reilly, JJ Harding, KH Yu, A Cercek, E Hollywood, ...

A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC).

MA Lowery, E Jordan, Y Kemel, S Mukherjee, A Cercek, NE Kemeny, ...

A situation where hepatocellular carcinoma (HCC) may be more common in women than men: Clinical and genetic patterns of non risk-factored HCC.

IH El Dika, JJ Harding, M Capanu, MF Berger, D Rebibo, M Rusek, ...

Ablative radiotherapy doses for locally advanced: pancreatic cancer (LAPC)

CH Crane, EM O’Reilly

Acceptability and effects of values-based outpatient advance care planning (ACP) in gastrointestinal (GI) cancers.

AS Epstein, EM O'Reilly, AE Volandes, E Shuk, DR Romano, W Breitbart

Acceptability and effects of values-based outpatient advanced care planning (ACP) in gastrointestinal (GI) cancers.

AS Epstein, EM O'Reilly, AE Volandes, Y Li, E Shuk, W Breitbart

Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of …

CS Fuchs, D Niedzwiecki, HJ Mamon, JE Tepper, X Ye, RS Swanson, ...

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline …

MHG Katz, FS Ou, JM Herman, SA Ahmad, B Wolpin, R Marsh, S Behr, ...

Alliance for clinical trials in oncology trial A021501: Preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable …

MHG Katz, FS Ou, J Herman, SA Ahmad, BM Wolpin, RW Marsh, Q Shi, ...

An audit of a bariatric sleep service

E O'Reilly, C O'Boyle, L Doherty

An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses

N Vasan, MI Braghiroli, AN Shoushtari, RKG Do, M Edelweiss, ...

Biodistribution and radiation rose estimates for 89Zr-DFO-HuMab-5B1 (MVT-2163) in CA19-9 positive cancer: first-in-man results

J O'Donoghue, C Lohrmann, E O'Reilly, K Yu, M Lowery, S Lyashchenko, ...

Brain metastases (BM) in pancreatic ductal adenocarcinoma (PDAC): Clinical and molecular characteristics.

E Jordan, TJ Kaley, M Capanu, H Estrella, SD Leach, O Basturk, ...

Case report: primary acinar cell carcinoma of the liver treated with multimodality therapy

EJ Jordan, O Basturk, J Shia, DS Klimstra, W Alago, MI D’Angelica, ...

Chemotherapy and intensity-modulated radiation therapy for locally advanced pancreatic cancer achieves a high rate of R0 resection

F Huguet, C Hajj, CB Winston, W Shi, Z Zhang, AJ Wu, EM O’Reilly, ...

Clinical characterization of pancreatic ductal adenocarcinomas (PDAC) with mismatch repair (MMR) gene mutations.

ZI Hu, AM Varghese, J Shia, A Zervoudakis, MA Lowery, KH Yu, ...

Clinical impact of visceral thrombosis (VT) in pancreatic ductal adenocarcinoma (PDAC).

A Mier Hicks, M Raj, RKG Do, KH Yu, MA Lowery, AM Varghese, ...

Correlating ISEND and Tumor Mutation Burden (TMB) with Clinical Outcomes of Advanced Non-Small Cell Lung Cancer (ANSCLC) Patients on Nivolumab

W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ...

Do pancreas cancer stem cells play crucial role in survival outcome?

G Askan, IH Sahin, M Capanu, M Turkekul, KH Yu, MA Lowery, O Basturk, ...

Early-onset pancreatic ductal adenocarcinoma (PDAC) at Memorial Sloan Kettering Cancer Center (MSKCC).

S Kunte, S Sangli, A Lemor, MA Lowery, KH Yu, GK Abou-Alfa, ...

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic …

AP Venook, D Niedzwiecki, HJ Lenz, F Innocenti, B Fruth, JA Meyerhardt, ...

First-in-human study of 89Zr-DFO-HuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive …

C Lohrmann, E O'Reilly, J ODonoghue, KH Yu, N Pandit-Taskar, ...

Hepatobiliary Cancer

GK Abou-Alfa, E O'Reilly

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

IH Sahin, G Askan, ZI Hu, EM O’Reilly

Impact of care at Memorial Sloan Kettering Cancer Center (MSKCC): A comprehensive cancer center on overall survival (OS) in patients (pts) with AJCC stage IV pancreas …

F Boland, A Cheema, MA Lowery, KH Yu, AM Varghese, AS Epstein, ...

Impact of early FDG-PET directed intervention on preoperative therapy for locally advanced gastric cancer: A Cooperative Group random assignment phase II study (Alliance …

MA Shah, Q Shi, VE Strong, J Strasser, DH Ilson, L Kleinberg, S Iqbal, ...

Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.

KA Goodman, D Niedzwiecki, N Hall, TS Bekaii-Saab, X Ye, MO Meyers, ...

iSEND is an algorithmic model specific for advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors

W Park, V Florou, S Algaze, D Saravia, D Kwon, G Lopes

ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

W Park, D Kwon, A Desai, V Florou, D Saravia, J Warsch, YK Chae, ...

ISOLATED THROMBOCYTOSIS AND A MASS IN THE HEART

M Rufin, F Balogun, D Randlett

Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer

Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D

Molecular landscape of fibrolamellar carcinoma (FLC): Beyond the DNAJB1-PRKACA chimera.

IH El Dika, M Capanu, MF Berger, ME Arcila, R Benayed, JJ Harding, ...

Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing

D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, ...

Necuparanib combined with nab-paclitaxel+ gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.

EM O'Reilly, D Mahalingam, JM Roach, PJ Miller, ME Rosano, S Krause, ...

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

M Dhir, GK Malhotra, DPS Sohal, NA Hein, LM Smith, EM O’Reilly, ...

Neutrophil-rich inflammation and PD1/PD-L1 inhibitor resistance in advanced non-small cell lung cancer patients

W Park, S Algaze, V Florou, D Saravia, D Kwon, G Lopes

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer

T Golan, T Sella, EM O'Reilly, MHG Katz, R Epelbaum, DP Kelsen, ...

P1. 07-024 ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

W Park, D Kwon, A Desai, V Florou, D Saravia, J Warsch, YK Chae, ...

P1. 07-025 correlating ISEND and tumor mutation burden (TMB) with clinical outcomes of advanced non-small cell lung cancer (ANSCLC) patients on nivolumab

W Park, G Lopes, D Kwon, V Florou, YK Chae, J Warsch, A Ishkanian, ...

P2. 07-037 Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients Receiving Nivolumab

W Park, D Kwon, D Saravia, A Desai, J Warsch, F Vargas, M El Dinali, ...

P3. 02b-092 Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose: Topic: EGFR Clinical

W Park, R Mudad

P3. 02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab: Topic: IT Biomarkers

D Saravia, B Laderian, W Park, A Desai, F Vargas, R Elias, S Warsch, ...

Pancreas adenocarcinoma: novel therapeutics

BA Krantz, HY Kenneth, EM O’Reilly

Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology

MA Tempero, MP Malafa, M Al-Hawary, H Asbun, A Bain, SW Behrman, ...

Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies

M Chiaravalli, M Reni, EM O'Reilly

Phase IB trial of ADI-PEG 20 (A) plus nab-paclitaxel (nab-P) and gemcitabine (gem) in patients with advanced pancreatic cancer (PC).

MA Lowery, JJ Harding, KH Yu, DP Kelsen, JS Bomalaski, DC Glassman, ...

Preface: pancreas adenocarcinoma

EM O'Reilly, L Zheng

Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients

J Chakraborty, L Langdon-Embry, KM Cunanan, JG Escalon, PJ Allen, ...